Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol Oncol 2004 Jul;94(1):147-51 PMID: 15262133

Abstract

OBJECTIVE: Pegylated liposomal doxorubicin (PLD) is currently utilized in the management of several solid tumors. While PLD has been shown to be less cardiotoxic than doxorubicin, the safety of prolonged administration (e.g., >or=6 cycles) of the agent remains undefined.

METHODS: A retrospective chart review was performed of the Cleveland Clinic experience from 1997 to 2003 with the prolonged (>or=6 cycles) use of PLD in individuals with gynecologic malignancies. PLD was administered at doses ranging from 20 to 40 mg/m(2) (infused over 1-2 h) with treatment repeated every 4-6 weeks. While on therapy, patients underwent routine evaluation for toxicity, including the performance of multigated acquisition (MUGA) scans for determination of left ventricular ejection fraction (LVEF).

RESULTS: Twenty-two patients (18 ovarian cancer; 3 primary peritoneal cancer, 1 endometrial cancer) met the criteria for inclusion in this analysis. This population had received a median of 4 (range 1-8) chemotherapy regimens before initiation of PLD. No patient had previously received doxorubicin. The median number of PLD cycles and cumulative dose of LD delivered were 8 (range 6-26) and 483 mg/m(2) (256-1699 mg/m(2)), respectively. One or more MUGA scans were obtained in 14 (64%) patients. No patient experienced clinical evidence (physical findings, symptoms) of heart failure. There were no dose reductions due to cardiac dysfunction, and no patient experienced a decline in LVEF to <50%, or a >or=10% reduction compared to a baseline value.

CONCLUSIONS: Prolonged therapy with PLD is possible in appropriately selected patients with advanced gynecologic malignancies. In this clinical setting, cardiac dysfunction does not appear to be a toxicity, which limits the duration of treatment. The development of evidence-based guidelines for monitoring cardiac function in this patient population would be quite useful.

Author List

Uyar D, Kulp B, Peterson G, Zanotti K, Markman M, Belinson J

Author

Denise S. Uyar MD Associate Professor in the Obstetrics and Gynecology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Aged
Aged, 80 and over
Antibiotics, Antineoplastic
Dose-Response Relationship, Drug
Doxorubicin
Drug Administration Schedule
Endometrial Neoplasms
Female
Gated Blood-Pool Imaging
Heart Diseases
Humans
Middle Aged
Ovarian Neoplasms
Peritoneal Neoplasms
Retrospective Studies
Ventricular Function, Left



View this publication's entry at the Pubmed website PMID: 15262133
jenkins-FCD Prod-141 f776ee82366dc5656a368d51cce32734d2f9b9a0